课题基金 / 基金详情

Heparan Sulfate in Skeletal Development and Diseases

Heparan Sulfate in Skeletal Development and Diseases
硫酸乙酰肝素在骨骼发育和疾病中的作用
批准号:
8698105
负责人:
YU YAMAGUCHI
金额:
$42.9万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-07 至 2019-03-31

项目摘要

项目成果

YU YAMAGUCHI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Multiple hereditary exostoses (MHE) is an autosomal dominant bone disorder caused by heterozygous mutations of EXT1 or EXT2, which jointly encode a glycosyltransferase essential for heparan sulfate biosynthesis. MHE is the most common genetic bone dysplasia and thought to affect several thousand Americans. During the current funding cycle, we elucidated a long- standing puzzle concerning the genetic mechanism of MHE. Specifically, we demonstrated that loss of heterozygosity modeled via stochastic conditional knockout results in the recapitulation of essentially all human MHE phenotypes. Based on this achievement and novel questions revealed by these studies, we will explore further this debilitating disease, with goals of understanding its complete pathogenic mechanism and identifying novel biomarkers and potential therapeutic targets. We propose the following aims. 1. Determine the origin of osteochondroma: While our studies elucidated the genetic mechanisms of osteochondromatogenesis, the cellular mechanisms by which a small number of Ext1 null cells develop into osteochondromas remains almost entirely elusive. One of the critical issues is whether osteochondromas are originated either from growth plate chondrocytes or from the perichondrium. We will perform perichondrium-specific Ext1 knockout and the analysis of perichondrial progenitor cells lacking Ext1 to address this issue. 2. Determine the affected signaling pathway that is critical for osteochondromatogenesis: Another critical issue is what is the defective signaling pathway directly responsible for osteochondromatogenesis. Based on strong preliminary evidence, we will focus on the BMP pathway and determine whether aberrant BMP signaling is the main molecular culprit underlying the disease. 3. Genome-wide analysis of osteochondroma transcriptome: We will perform a state-of-the-art bioinformatics study to determine transcriptomic changes that define osteochondroma. By applying the weighted gene coexpression network analysis on RNA microarray data sets, we will identify molecular signatures that distinguish osteochondroma from normal chondrocytes and potential genetic biomarkers to predict the future severity and recurrence of osteochondroma in MHE patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microglial heparan sulfate in the modulation of APOE function and neurodegeneration
Microglial heparan sulfate in the modulation of APOE function and neurodegeneration
Heparan sulfate in neurophysiology and neurological disorders
Heparan sulfate in neurophysiology and neurological disorders
海外基金